Arterial Thrombosis
11
3
3
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
27%
3 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (11)
Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
Intra-arterial Thrombolysis After Successful Thrombectomy for Acute Ischemic Stroke in the Posterior Circulation (IAT-TOP)
JETi Lower Extremity Arterial Thrombosis
Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
PeriOperative ISchemic Evaluation-3 Trial
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus
Arterial Thrombosis and Inflammatory Bowel Disease: a Series of 6 Cases and Literature Review